Τίτλος:
Comparison of a rapid fluorescence immunochromatographic test with an enzyme-linked immunosorbent assay for measurement of SARS-CoV-2 spike protein antibody neutralizing activity
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: SARS-CoV-2 Spike protein Receptor Binding Domain neutralizing antibodies (NAbs-RBD) inhibit the viral binding to angiotensin-converting enzyme 2 (ACE2) receptors. We compared an ELISA and a fluorescence immunochromatography (FIC) method in NAbs-RBD detection after COVID-19 immunization. Method: Serum samples from healthcare workers (HCWs) vaccinated with BNT162b2 were collected one and four months after the second dose. NAbs-RBD (%) detection was performed using ELISA cPass™ (FDA approved) and FIC n-AbCOVID-19® assays. Results: Samples from 200 HCWs [median age (IQR): 45(35−53)] were tested with both assays. There was a good qualitative agreement between the two methods [AUC: 0.92(95%C.I.: 0.89–0.94, P-value:0.007)]. NAbs-RBD (%), one and four months after immunization, were significantly lower with FIC compared to ELISA for all age groups (P-value<0.0001). The quantitative comparison between FIC and ELISA detected slight agreement one month after the second dose [(Lin's Concordance Correlation Coefficient (CCC): 0.21(95%CI: 0.15–0.27)] which improved four months after the second dose [CCC: 0.6(95%CI: 0.54–0.66)]. Conclusion: FIC had good qualitative agreement with ELISA in the detection of positive NAbs-RBD (%) and could be an alternative for rapid NAbs-RBD (%) testing. © 2023
Συγγραφείς:
Filippatos, F.
Tatsi, E.-B.
Papagiannopoulos, C.
Syriopoulou, V.
Michos, A.
Περιοδικό:
Journal of Virological Methods
Λέξεις-κλειδιά:
tozinameran; bnt 162 vaccine; coronavirus spike glycoprotein; neutralizing antibody; spike protein, SARS-CoV-2; virus antibody, adult; age distribution; aged; area under the curve; Article; bootstrapping; centrifugation; cohort analysis; comparative study; controlled study; coronavirus disease 2019; correlation coefficient; drug efficacy; drug safety; enzyme linked immunosorbent assay; female; fluorescence; health care personnel; human; immunization; immunoaffinity chromatography; major clinical study; male; middle aged; optical density; qualitative analysis; quantitative analysis; receiver operating characteristic; young adult; coronavirus disease 2019; enzyme linked immunosorbent assay; Severe acute respiratory syndrome coronavirus 2, Antibodies, Neutralizing; Antibodies, Viral; BNT162 Vaccine; COVID-19; Enzyme-Linked Immunosorbent Assay; Humans; SARS-CoV-2; Spike Glycoprotein, Coronavirus
DOI:
10.1016/j.jviromet.2023.114728
